GlassScriptPhysician profile
Marcia M Harris
NPI 1104078674
$155,618.06
in general payments reported to CMS, 2019-2025
8 companies · $30K in 2025
The $30K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $26K · 2022: $29K · 2023: $50K · 2024: $21K · 2025: $30K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $77K · Travel and Lodging: $11K · Consulting Fee: $9,376 · Food and Beverage: $4,151 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $76,539.00 |
| Travel and Lodging | $10,595.64 |
| Consulting Fee | $9,375.50 |
| Food and Beverage | $4,150.79 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $125,007.29 | 2021-2024 | Ingrezza |
| Janssen Pharmaceuticals, INC | $29,830.15 | 2023-2025 | Invega Sustenna, Invega Trinza, Invega |
| Janssen Scientific Affairs, LLC | $224.08 | 2025 | Invega Sustenna |
| Teva Pharmaceuticals USA, INC. | $185.33 | 2023-2025 | Uzedy, Austedo, Austedo Xr |
| Abbvie INC. | $177.37 | 2022-2023 | |
| Indivior INC. | $90.02 | 2022-2024 | Perseris |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $69.23 | 2021-2023 | |
| Alkermes, INC. | $34.59 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcia Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.